← Eichor
Study identifier: NCT05363748 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Renal Artery Fibromuscular Dysplasia Registry

Condition: Renal Artery Fibromuscular Dysplasia  ·  Sponsor: Shanghai Jiao Tong University School of Medicine

PhaseN/A
Planned participants500
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

1. Study name: A Prospective Study of the Renal artery fibromuscular dysplasia Registry in China 2. Rationale: Fibromuscular dysplasia (FMD) is an idiopathic systemic noninflammatory arterial disease resulting in narrowing of medium-sized arteries. Renal arteries are most commonly involved vessels, although it can also affect arteries in other vascular territories. Renal artery FMD is the second frequent cause of renovascular hypertension , especially in adolescents. The pathogenesis of FMD is still not understood. There were little Asians in the United States and the European/International FMD registry. 3. Objective: 1) To describe the characteristics of renal artery FMD; 2) To identify environmental/ hormonal factors and exposures (for example smoking) associated with the onset and progression of renal artery FMD; 3)To identify baseline characteristics of the disease associated with an increased risk of complications such as dissections, aneurysms, stroke or myocardial infarction; 4) To provide evidence-based algorithms for the management and follow-up of patients with renal artery FMD; 5) To establish a comprehensive imaging resource including a wide range of presentations of renal artery FMD. 4. Study design: Prospective, multi-center, observational study. 5. Study population: renal artery fibromuscular dysplasia 6. Data Collections: 1) Data on demographic characteristics, clinical characteristics, blood routine, biochemical and plasmic electrolytes and vascular imaging w…

This description comes directly from the study's public registry record.

Talk to the study team

Jiguang Wang, MD, PhD  ·  +86-21-64370045  ·  jiguangw@163.com

Jiguang Wang, MD, PhD  ·  +86-21-64370045  ·  iguang_wang_jgw@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05363748